Ocular actions of platelet-activating factor: clinical implications

被引:9
|
作者
Nitoda, Eirini [2 ]
Moschos, Marilita M. [3 ]
Mavragani, Clio P. [1 ]
Koutsilieris, Michael [1 ]
机构
[1] Univ Athens, Sch Med, Dept Expt Physiol, Goudi 11527, Greece
[2] Univ Athens, Sch Med, Dept Ophthalmol, Dept Expt Physiol, Athens 15125, Greece
[3] Univ Athens, Sch Med, Dept Ophthalmol, Athens 14578, Greece
关键词
inflammatory mediators; ocular inflammation; PAF; PAF antagonists; NECROSIS-FACTOR-ALPHA; EXPERIMENTAL ALLERGIC CONJUNCTIVITIS; FACTOR RECEPTOR ANTAGONIST; FACTOR ACETYLHYDROLASE; FACTOR PAF; SIGNAL-TRANSDUCTION; OXIDATIVE STRESS; LIPID MEDIATORS; GUINEA-PIGS; PROINFLAMMATORY CYTOKINES;
D O I
10.1517/14728222.2012.712961
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Introduction: To summarize the currently available evidence of platelet-activating factor (PAF) implication in the pathogenesis of inflammatory ocular diseases. Areas covered: PAF is a potent mediator of inflammation, implicated in the pathogenesis of chronic inflammatory disorders, allergic reactions, oncogenic transformation, wound repair and hypoxia-induced angiogenesis. It seems to be involved in the protection of ocular surface against various harmful agents through inflammatory processes, which can lead to chronic allergic reactions or even corneal neovascularization and haze, if they do not undergo regulation. Pathogenesis of uveitis, which is significant cause for the blurring of the visual system, has also been associated with PAF's activity. The hypoxia and the breakdown of the blood-retina barrier, observed in severe vascular retinal diseases, such as age-related macular degeneration and diabetic retinopathy, are associated with PAF ocular activity. Expert opinion: Understanding the pathophysiology of vision threatening diseases could enhance clinical treatment and encourage experimental studies, which could be based on potential beneficial effects of new agents, such as PAF antagonists.
引用
收藏
页码:1027 / 1039
页数:13
相关论文
共 50 条
  • [21] Platelet-Activating Factor and Pain
    Tsuda, Makoto
    Tozaki-Saitoh, Hidetoshi
    Inoue, Kazuhide
    BIOLOGICAL & PHARMACEUTICAL BULLETIN, 2011, 34 (08) : 1159 - 1162
  • [22] NEPHROPATHIES AND PLATELET-ACTIVATING FACTOR
    PIROTZKY, E
    COLLIEZ, P
    GUILMARD, C
    BRAQUET, P
    PEDIATRIE, 1989, 44 (03): : 163 - 167
  • [23] Platelet-activating factor and angiogenesis
    Camussi, G
    Montrucchio, G
    Lupia, E
    Arese, M
    Bussolino, F
    PLATELET-ACTIVATING FACTOR AND RELATED LIPID MEDIATORS 2: ROLES IN HEALTH AND DISEASE, 1996, 416 : 231 - 234
  • [24] Seminal platelet-activating factor
    Roudebush, William E.
    SEMINARS IN THROMBOSIS AND HEMOSTASIS, 2007, 33 (01): : 69 - 74
  • [25] Platelet-activating factor receptor
    Ishii, S
    Nagase, T
    Shimizu, T
    PROSTAGLANDINS & OTHER LIPID MEDIATORS, 2002, 68-9 : 599 - 609
  • [26] Platelet-activating factor acetylhydrolases
    Stafforini, DM
    McIntyre, TM
    Zimmermann, GA
    Prescott, SM
    JOURNAL OF BIOLOGICAL CHEMISTRY, 1997, 272 (29) : 17895 - 17898
  • [27] PLATELET-ACTIVATING FACTOR TODAY
    VARGAFTIG, BB
    BENVENISTE, J
    TRENDS IN PHARMACOLOGICAL SCIENCES, 1983, 4 (08) : 341 - 343
  • [28] Platelet-activating factor receptor
    Honda, Z
    Ishii, S
    Shimizu, T
    JOURNAL OF BIOCHEMISTRY, 2002, 131 (06): : 773 - 779
  • [29] Platelet-activating factor in the CNS
    Maclennan, KM
    Smith, PF
    Darlington, CL
    PROGRESS IN NEUROBIOLOGY, 1996, 50 (5-6) : 585 - 596
  • [30] Platelet-activating factor inhibits the secretion of platelet-activating factor acetylhydrolase by human decidual macrophages
    Narahara, H
    Kawano, Y
    Nasu, K
    Yoshimatsu, J
    Johnston, JM
    Miyakawa, I
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2003, 88 (12): : 6029 - 6033